Mesoblast Advances Ryoncil Registrational Trial in Duchenne Muscular Dystrophy with FDA Clearance

• FDA grants IND clearance for Ryoncil registrational trial in Duchenne Muscular Dystrophy
• Trial to enrol 76 children aged 5 to 9 years with primary endpoint of time-to-stand at nine months
• Mesoblast partners with Parent Project Muscular Dystrophy to support patient recruitment
• Ryoncil is FDA-approved for steroid-refractory acute graft-versus-host disease in children